Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.
Seow, C H
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. [electronic resource] - Gut Jan 2010 - 49-54 p. digital
Publication Type: Journal Article
1468-3288
10.1136/gut.2009.183095 doi
Acute Disease
Adolescent
Adult
Aged
Antibodies, Monoclonal--blood
Antibody Formation
Cohort Studies
Colectomy
Colitis, Ulcerative--blood
Colonoscopy
Drug Administration Schedule
Drug Monitoring--methods
Female
Gastrointestinal Agents--blood
Humans
Infliximab
Male
Middle Aged
Prognosis
Remission Induction
Risk Assessment--methods
Treatment Outcome
Young Adult
Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. [electronic resource] - Gut Jan 2010 - 49-54 p. digital
Publication Type: Journal Article
1468-3288
10.1136/gut.2009.183095 doi
Acute Disease
Adolescent
Adult
Aged
Antibodies, Monoclonal--blood
Antibody Formation
Cohort Studies
Colectomy
Colitis, Ulcerative--blood
Colonoscopy
Drug Administration Schedule
Drug Monitoring--methods
Female
Gastrointestinal Agents--blood
Humans
Infliximab
Male
Middle Aged
Prognosis
Remission Induction
Risk Assessment--methods
Treatment Outcome
Young Adult